BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao S, Jiang X, Tan C, Fu M, Xiong W, Ji D, Lv J. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations. J Mol Model 2021;27:337. [PMID: 34725737 DOI: 10.1007/s00894-021-04964-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Cao S, Tan C, Fei A, Hu G, Fu M, Lv J. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations. J Mol Model 2022;29:24. [PMID: 36576611 DOI: 10.1007/s00894-022-05429-9] [Reference Citation Analysis]
2 Zheng G, Li M, Zhang J, Liu W, Jiang L, Liang W, Wang J, Shi H, Kang Z, Zhou B. A computational study to reveal selpercatinib resistance to RET kinase double mutant V804M/Y806C. Chem Pap . [DOI: 10.1007/s11696-022-02479-4] [Reference Citation Analysis]
3 Zhou S, Yang B, Xu Y, Gu A, Peng J, Fu J. Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy. J Mol Model 2022;28:247. [PMID: 35932378 DOI: 10.1007/s00894-022-05254-0] [Reference Citation Analysis]
4 Liu C, Zhang Y, Zhang Y, Liu Z, Mao F, Chai Z. Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A. Molecules 2022;27:4655. [DOI: 10.3390/molecules27144655] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]